Bevacizumab as treatment option for recurrent respiratory papillomatosis: a systematic review
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1434-4726
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Bevacizumab as treatment option for recurrent respiratory papillomatosis: a systematic review ; day:24 ; month:4 ; year:2022 ; pages:1-12
European archives of oto-rhino-laryngology and head & neck ; (24.4.2022), 1-12
- Creator
-
Pogoda, Louis
Ziylan, Fuat
Smeeing, Diederik P. J.
Dikkers, Frederik G.
Rinkel, Rico N. P. M.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s00405-022-07388-6
- URN
-
urn:nbn:de:101:1-2022070620525944075640
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:22 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Pogoda, Louis
- Ziylan, Fuat
- Smeeing, Diederik P. J.
- Dikkers, Frederik G.
- Rinkel, Rico N. P. M.
- SpringerLink (Online service)
Other Objects (12)
Bevacizumab for patients with recurrent multifocal glioblastomas
Recurrent respiratory infections in elderly
Re-irradiation combined with bevacizumab for recurrent glioblastoma beyond bevacizumab failure: survival outcomes and prognostic factors
Radiotherapy versus combination radiotherapy-bevacizumab for the treatment of recurrent high-grade glioma: a systematic review
Clinical outcomes with bevacizumab-containing and non-bevacizumab–containing regimens in patients with recurrent glioblastoma from US community practices
Use of Bevacizumab in recurrent glioblastoma: a scoping review and evidence map
Circulating PD-L1 levels change during bevacizumab-based treatment in recurrent glioma
Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer
Respiratory syncytial virus prophylaxis for prevention of recurrent childhood wheeze and asthma: a systematic review
Everolimus and Bevacizumab in the Management of Recurrent, Progressive Intracranial NF2 Mutated Meningioma
Recurrence pattern analysis after re-irradiation with bevacizumab in recurrent malignant glioma patients
Bevacizumab for patients with recurrent gliomas presenting with a gliomatosis cerebri growth pattern
Bevacizumab for patients with recurrent multifocal glioblastomas
Recurrent respiratory infections in elderly
Re-irradiation combined with bevacizumab for recurrent glioblastoma beyond bevacizumab failure: survival outcomes and prognostic factors
Radiotherapy versus combination radiotherapy-bevacizumab for the treatment of recurrent high-grade glioma: a systematic review
Clinical outcomes with bevacizumab-containing and non-bevacizumab–containing regimens in patients with recurrent glioblastoma from US community practices
Use of Bevacizumab in recurrent glioblastoma: a scoping review and evidence map
Circulating PD-L1 levels change during bevacizumab-based treatment in recurrent glioma
Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer
Respiratory syncytial virus prophylaxis for prevention of recurrent childhood wheeze and asthma: a systematic review
Everolimus and Bevacizumab in the Management of Recurrent, Progressive Intracranial NF2 Mutated Meningioma
Recurrence pattern analysis after re-irradiation with bevacizumab in recurrent malignant glioma patients
Bevacizumab for patients with recurrent gliomas presenting with a gliomatosis cerebri growth pattern
Bevacizumab for patients with recurrent multifocal glioblastomas
Recurrent respiratory infections in elderly
Re-irradiation combined with bevacizumab for recurrent glioblastoma beyond bevacizumab failure: survival outcomes and prognostic factors
Radiotherapy versus combination radiotherapy-bevacizumab for the treatment of recurrent high-grade glioma: a systematic review
Clinical outcomes with bevacizumab-containing and non-bevacizumab–containing regimens in patients with recurrent glioblastoma from US community practices
Use of Bevacizumab in recurrent glioblastoma: a scoping review and evidence map
Circulating PD-L1 levels change during bevacizumab-based treatment in recurrent glioma
Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer
Respiratory syncytial virus prophylaxis for prevention of recurrent childhood wheeze and asthma: a systematic review
Everolimus and Bevacizumab in the Management of Recurrent, Progressive Intracranial NF2 Mutated Meningioma
Recurrence pattern analysis after re-irradiation with bevacizumab in recurrent malignant glioma patients